Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

January 16, 2025

Primary Completion Date

November 30, 2031

Study Completion Date

November 30, 2031

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

ABBV-291

Intravenous Infusion

Trial Locations (10)

3065

RECRUITING

St Vincent's Hospital Melbourne /ID# 261664, Fitzroy Melbourne

22031

RECRUITING

Virginia Cancer Specialists - Fairfax /ID# 265082, Fairfax

28078

RECRUITING

Carolina BioOncology Institute /ID# 265259, Huntersville

78705

RECRUITING

Texas Oncology - Central/South Texas /ID# 270946, Austin

91120

RECRUITING

Hadassah Medical Center-Hebrew University /ID# 261658, Jerusalem

97401

RECRUITING

Willamette Valley Cancer Institute and Research Center /ID# 270945, Eugene

6423906

RECRUITING

Tel Aviv Sourasky Medical Center /ID# 261659, Tel Aviv

84119-3602

RECRUITING

START Mountain Region /ID# 267592, West Valley City

464-8681

RECRUITING

Aichi Cancer Center /ID# 267471, Nagoya

135-8550

RECRUITING

The Cancer Institute Hospital Of JFCR /ID# 267470, Koto-ku

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AbbVie

INDUSTRY